Get the Stockscreener App
2.95
0.34%
0.01
After Hours:
2.95
Akari Therapeutics Plc Adr stock is traded at $2.95, with a volume of 1,720.
It is up +0.34% in the last 24 hours and down -22.98% over the past month.
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
See More
Previous Close:
$2.94
Open:
$3
24h Volume:
1,720
Relative Volume:
0.09
Market Cap:
$35.83M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-8.4746
EPS:
-0.3481
Net Cash Flow:
-
1W Performance:
-7.81%
1M Performance:
-22.98%
6M Performance:
+58.18%
1Y Performance:
-25.32%
1-Day Range:
$2.91
$3.00
1-Week Range:
$2.57
$3.85
52-Week Range:
$1.0775
$4.40
Akari Therapeutics Plc Adr Stock (AKTX) Company Profile
Name
Akari Therapeutics Plc Adr
Sector
Industry
Phone
(646) 350-0702
Address
22 BOSTON WHARF ROAD, BOSTON
Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-04-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Neutral |
| Sep-22-17 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-31-17 | Upgrade | Chardan Capital Markets | Sell → Neutral |
| Apr-17-17 | Reiterated | Chardan Capital Markets | Sell |
| Jul-11-16 | Initiated | Chardan Capital Markets | Sell |
View All
Akari Therapeutics Plc Adr Stock (AKTX) Latest News
Akari Therapeutics PlcADR (AKTX) Price Target Increased by 45.45% to 81.60 - MSN
Akari Therapeutics appoints Rob Bazemore to board - Investing.com
Akari Therapeutics appoints Rob Bazemore to board - Investing.com India
Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics - StockTitan
Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy - StockTitan
Akari Therapeutics shareholders approve board and auditors - Investing.com India
Akari Therapeutics shareholders approve board and auditors By Investing.com - Investing.com India
Zoomcar announces departure of President Adarsh Menon By Investing.com - Investing.com
Phillips Edison expands board, appoints Devin Murphy By Investing.com - Investing.com India
Goldman Sachs raises Birkenstock target to $59.50, keeps neutral stance By Investing.com - Investing.com
Akari Therapeutics shareholders approve board and auditors By Investing.com - Investing.com
Shopify’s market position 'promising for growth', Evercore ISI sees stock upside - Investing.com
Akari Therapeutics secures $7.6 million in private financing By Investing.com - Investing.com
Akari Therapeutics secures $7.6 million in private financing By Investing.com - Investing.com UK
Closing Figures Unveiled: Akari Therapeutics Plc ADR (AKTX) Drop -4.19, Closes at 1.72 – DWinneX - The Dwinnex
Arbe Robotics sees high demand for convertible debt By Investing.com - Investing.com
Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights - GlobeNewswire Inc.
Insmed executive sells over $270k in company stock By Investing.com - Investing.com
Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics - GlobeNewswire Inc.
Dialing Up Nights Out: Heineken® & Bodega Launch the No-Frills 'Boring Phone' | GlobeNewswire by notified - NTB Kommunikasjon
Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights - GlobeNewswire Inc.
India opposition asks Modi government to question Foxconn hiring practices By Reuters - Investing.com
The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer I - Benzinga
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Markets Insider
AKTXAkari Therapeutics plc ADR (0.01 USD) Latest Stock News & Market Updates - StockTitan
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Sh - Benzinga
The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 T - Benzinga
48 Stocks Moving In Friday's Mid-Day SessionAfya (NASDAQ:AFYA) - Benzinga
GCI: Best & Worst Performing Small Cap Stocks for July 19, 2019 - StockNews.com
52 Biggest Movers From YesterdayAyala Pharmaceuticals (OTC:ADXS), Altisource Asset Mgmt (AMEX:AAMC) - Benzinga
'Flying Whale' Blimp That Never Lands Joins Global Airship Race - Bloomberg
CRISPR Therapeutics (CRSP) Jumps: Stock Rises 12.1% - Investing.com
22 Stocks Moving In Monday's Pre-Market SessionAkari Therapeutics (NASDAQ:AKTX), argenx (NASDAQ:ARGX) - Benzinga
Mid-Morning Market Update: Markets Fall; Initial Jobless Claims Drop to 259,000Akari Therapeutics (NAS - Benzinga
25 Stocks Moving In Tuesday's Pre-Market SessionAkari Therapeutics (NASDAQ:AKTX), Aurinia Pharmaceutic - Benzinga
Mid-Afternoon Market Update: Dow Drops 50 Points; TRC Companies Shares Spike Higher - Nasdaq
Angion Biomedica (ANGN) Stock Price, News & Analysis - MarketBeat
Lockheed Lands Airship Deal as Oil Industry Spurs Blimp Revival - Bloomberg
Two Stocks That Have Deerfield Management And Anchor Bolt Capital Excited - Insider Monkey
Akari Therapeutics Plc Adr Stock (AKTX) Financials Data
There is no financial data for Akari Therapeutics Plc Adr (AKTX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):